10x Genomics, Inc. (TXG) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2026. 10x Genomics, Inc. is a life sciences technology company providing integrated research solutions for single-cell and spatial analysis, including instruments (Chromium, Visium, Xenium), consumables, and software. The company operates as a single reportable segment.
Key Financial Metrics
| Metric | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Total Revenue | $151.0M | $172.9M | $301.9M | $327.8M |
| Products & Services Revenue | $149.1M | $145.2M | $299.0M | $283.0M |
| License & Royalty Revenue | $1.9M | $27.8M | $2.9M | $44.8M |
| Gross Profit | $112.5M | $125.1M | $218.7M | $230.5M |
| Gross Margin | 74% | 72% | 72% | 70% |
| Net Income (Loss) | $(17.9M) | $34.5M | $(31.4M) | $0.2M |
| Operating Cash Flow (YTD) | $43.1M | $52.1M | N/A | N/A |
| Cash & Marketable Securities | $552.0M | N/A | N/A | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 13% QoQ and 8% YTD compared to 2025. This was primarily driven by a 93% drop in license and royalty revenue, which was inflated in 2025 by one-time settlements with Bruker ($27.3M) and Vizgen ($16.8M).
- Core Business Growth: Excluding one-time royalties, core products and services revenue grew 3% in Q2 and 6% YTD. Consumables revenue increased 7% QoQ and 10% YTD, while instrument revenue declined 47% QoQ and 35% YTD.
- Profitability: The company reported a net loss of $17.9M in Q2 2026, compared to a net income of $34.5M in Q2 2025. The prior year's income included a $40.7M gain on settlement.
- Margin Expansion: Gross margin improved to 74% in Q2 2026 (from 72% in Q2 2025) due to lower manufacturing costs, tariff refunds, and reduced inventory write-downs.
- Acquisition: On June 8, 2026, the company acquired Proteintech Genomics, Inc. (PTG) for $6.1M in cash to expand proteomics capabilities.
Guidance, Outlook, and Risks
- Outlook: Management expects revenues to moderately increase in 2026 compared to 2025, excluding non-recurring license and royalty revenue. Operating expenses are expected to modestly decrease in 2026.
- Liquidity: As of June 30, 2026, the company held $552.0M in cash and marketable securities. Management believes this is sufficient to meet needs for at least the next 12 months. Capital expenditures are expected to be between $10M and $15M over the next 12 months.
- Legal Proceedings:
- Spatial Genomics/Caltech: Sued 10x in August 2026 alleging Xenium platform infringement.
- Parse Biosciences: Ongoing litigation regarding patent validity; trial scheduled for August 2026.
- Illumina & Element: 10x has filed suits against both companies alleging patent infringement; trials scheduled for 2028.
- Takara: Litigation settled in May 2026, resulting in $1.6M revenue recognition.
- Contingent Consideration: The company may pay up to $30.0M in future contingent consideration related to the Scale Biosciences acquisition if milestones are met.
Key Facts for Investor Verification
- Revenue Quality: Verify the sustainability of core revenue growth (consumables vs. instruments) given the significant drop in one-time royalty income compared to 2025.
- Instrument Sales: Investigate the 47% QoQ decline in instrument revenue and its impact on future consumables attach rates.
- Legal Exposure: Monitor the outcome of the August 2026 trial with Parse Biosciences and the new lawsuit filed by Spatial Genomics/Caltech regarding the Xenium platform.
- Acquisition Integration: Assess the strategic value and integration progress of the Proteintech Genomics (PTG) acquisition.
- Cash Burn vs. Generation: Confirm that operating cash flow remains positive despite the reported net loss, driven by non-cash adjustments like stock-based compensation.